Innovative Modular System Eliminates Glucocorticoid Receptors
Stress hormones often trigger a survival response in certain cancers, forcing tumor cells into a dormant state via specialized proteins known as glucocorticoid receptors. While this hibernation shields the cells from conventional treatments, completely disabling these receptors throughout the body triggers severe side effects due to their vital role in immune regulation. To overcome this hurdle, scientists at ETH Zurich engineered a targeted system that degrades these receptors inside tumors while utilizing light to shield surrounding healthy tissues.
Co-lead author Robin Scheuplein noted that the system leverages existing medical technologies, offering a practical pathway for localized oncological therapies. In laboratory tests conducted on cultured lung cancer cells, the treatment successfully dismantled the glucocorticoid receptors and altered gene expression, prompting the cells to exit hibernation. The long-term vision involves injecting this molecular switch directly into a tumor and using a light barrier to neutralize any therapeutic components that leak into adjacent healthy areas.
Read Also
Despite these promising in vitro results, Scheuplein emphasized that the approach must still be verified in living organisms before clinical trials can begin. A current technical limitation involves light penetration, which only reaches a few millimeters into biological tissue, necessitating the use of endoscopes for localized delivery in organs like the lungs. To address deeper malignancies safely, the research team aims to adapt the molecular switches to respond to longer wavelengths, such as near-infrared light, which penetrates tissue more effectively.
This innovative platform features a highly adaptable modular design capable of being recalibrated to shut down alternative cellular receptors beyond the glucocorticoid family. The researchers intend to expand the system to target estrogen receptors linked to hormone-dependent breast cancer as well as androgen receptors driving advanced prostate cancer, positioning the technology as a multi-purpose tool in next-generation high-precision oncology frameworks.